Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 49

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 49
---
 parties to further develop or commercialize
our diagnostic tests or therapeutic product candidates. Should we be required to obtain licenses to any third-party technology, including
any such patents required to manufacture, use, or sell our product candidates, such licenses may not be available to us on commercially
reasonable terms or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates
could cause us to abandon any related efforts, which could seriously harm our business and operations. The licensing or acquisition of
third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license
or acquire third-party intellectual property rights we may consider attractive or necessary. These established companies may have a competitive
advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition,
companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to obtain a license
under such intellectual property rights, any such license may be non-exclusive, which may allow our competitors access to the same technologies
licensed to us.

Moreover, some of our owned and in-licensed patents
or patent applications or future patents may be co-owned with third parties. If we are unable to obtain an exclusive license to any such
third-party co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other
third parties, including our competitors, and our competitors could market competing diagnostic tests or therapeutic products and technology.
In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties,
and such cooperation may not be provided to us. Furthermore, our owned and in-licensed patents may be subject to a reservation of rights
by one or more third parties. Any of the foregoing could have a material adverse effect on our competitive position, business, financial
conditions, results of operations, and prospects.

| 23 |

Our competitive position depends on protection of our intellectual property.

Development and protection of our intellectual property
are critical to our business. If we do not adequately protect our intellectual property, or if competitors develop technologies incorporating
the same or similar technologies that already are in the public domain, those competitors may be able to develop similar technologies
to our own. Our success depends in part on our ability to obtain patent protection for our diagnostic tests, therapeutic products, or
processes in the U.S.